Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s share price fell 17.8% during mid-day trading on Tuesday. The stock traded as low as C$0.28 and last traded at C$0.30. 98,988 shares changed hands during mid-day trading, an increase of 20% from the average daily volume of 82,517 shares. The stock had previously closed at C$0.36.
Medicenna Therapeutics Stock Performance
The firm has a market cap of C$21.23 million, a P/E ratio of -1.05 and a beta of 2.49. The stock’s 50 day moving average is C$0.42 and its two-hundred day moving average is C$0.53. The company has a debt-to-equity ratio of 6.22, a current ratio of 1.25 and a quick ratio of 4.65.
Medicenna Therapeutics (TSE:MDNA – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported C($0.04) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative return on equity of 360.29% and a negative net margin of 533,640.00%. As a group, equities analysts predict that Medicenna Therapeutics Corp. will post -0.37 EPS for the current year.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.
Featured Articles
- Five stocks we like better than Medicenna Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
